Ultrasound-guided intraperitoneal cisplatin after the maximum cytoreductive surgery of pseudomyxoma peritonei
Bulletin of Alexandria Faculty of Medicine. 2008; 44 (4): 729-734
en Inglés
| IMEMR
| ID: emr-99555
ABSTRACT
In the past, pseudomyxoma peritonei was considered an incurable disease and often no active treatment was given. With the advent of cyto-reductive surgery, including peritonectomy procedures and intra peritoneal chemotherapy, long-term survival of these patients became actually possible. To study the impact of the intraperitoneal hyperthermic chemotherapy [cisplatin], when locally administered in patients who presented with pseudomyxoma peritonei and were treated by extensive cyto-reductive surgery. Nine patients with and. peritoneal adenomucinosis or carcinomatosis arising from the appendix who presented with a clinical picture of pseudomyxoma peritonei were diagnosed, and treated by cyto-reductive surgery followed by 6 cycles of ultrasound-guided intraperitoneal hyperthermic cisplatin. Following aggressive surgical approach and intraperitoneal chemotherapy, 7 patients had 1 year disease free survival, achieved independent activity in daily living and had an improved quality of life. The other 2 patients developed recurrences at 8 and 10 months following the completion of treatment. No major [grade III] texicities were observed. Pseudomyxoma peritonei is a treatable condition that may result in long-term disease free survival. Successful management can be achieved by combining cyto-reductive surgery and intraperitoneal hyperthermic chemotherapy
Buscar en Google
Índice:
IMEMR (Mediterraneo Oriental)
Asunto principal:
Patología
/
Procedimientos Quirúrgicos Operativos
/
Biopsia
/
Antígeno Carcinoembrionario
/
Tomografía Computarizada por Rayos X
/
Tasa de Supervivencia
/
Ultrasonografía
/
Cisplatino
/
Inyecciones Intraperitoneales
/
Metástasis de la Neoplasia
Límite:
Femenino
/
Humanos
/
Masculino
Idioma:
Inglés
Revista:
Bull. Alex. Fac. Med.
Año:
2008
Similares
MEDLINE
...
LILACS
LIS